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Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) is a common neurological disorder affecting 5 % of
children worldwide. A prevalent problem for children with ADHD is initial insomnia. The gold standard treatment to
manage ADHD symptoms is stimulant medications, which may exacerbate the severity of existing initial insomnia.
Currently, no gold standard treatment option exists for initial insomnia for these children. Melatonin, a hormone
and a popular natural health product, is commonly provided to children by parents and recommended by
healthcare providers, but high quality pediatric evidence is lacking.
Methods/design: This trial is a multicenter randomized triple-blind, placebo-controlled, parallel-group,
randomized, controlled trial (RCT), in which each participant is offered an N-of-1 trial. An N-of-1 trial is a
multiple-crossover, randomized, controlled trial conducted in a single individual. For the N-of-1 trial, each
participant will undergo three pairs of treatment/placebo periods; each period is 1 week in length. Half the
participants will have melatonin in the first period, the other half will start with placebo, and this will make up
the parallel-group RCT. The primary outcome will be mean difference in sleep onset latency as measured by
sleep diaries. A comparison of treatment effects yielded by the RCT data versus the aggregated N-of-1 trial
data will also be assessed.
Discussion: This trial will provide rigorous evidence for the effectiveness of melatonin in children with ADHD
on stimulants who experience initial insomnia. Further, this study will provide the first prospectively planned
head-to-head comparison of RCT data with pooled data from a series of N-of-1 trials. Aggregated N-of-1 trials
may be a powerful tool to produce high quality clinical trial evidence.
Trial registration numbers: ClinicalTrials.gov, NCT02333149. Registered on 16 December 2014. Australian New
Zealand Clinical Trials Registry, ACTRN12614000542695. Registered on 21 May 2014.
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Background
Attention-deficit/hyperactivity disorder (ADHD) is the
most common neurodevelopmental disorder in children
[1, 2] affecting 5–13 % of Canadian, Australian, and
American school-aged children [3, 4]. ADHD is charac-
terized by inattention, hyperactivity, and impulsivity,
which negatively interfere with the child’s socialization
and education. It has long-term ramifications through-
out adulthood [5], leading to an academic underachieve-
ment, language and literacy problems, fewer years of
completed schooling, lower-ranking employment, and
lower achieved social class than control groups [6–11].
The utilization and cost of healthcare services for chil-
dren with ADHD in the United States are approxi-
mately double those for children without ADHD.
Pelham and colleagues reported that in 2005, the soci-
etal cost of childhood ADHD was approximately $42.5
billion USD [12, 13].
The first line of treatment for ADHD is stimulant
medication, which is effective in 70–90 % of school-aged
children [14–16]. The most commonly prescribed stimu-
lants, methylphenidate, and amphetamines experienced
a fivefold increase in use from 1987 to 2002 among chil-
dren in the United States [17]. Similarly, between 1990
and 2000, Australia saw a fivefold increase in the num-
ber of children and adolescents with ADHD who had
commenced taking stimulant medication [18]. Al-
though stimulants help to effectively manage ADHD
symptoms, they are also associated with a number of
adverse events: initial insomnia is among the most
commonly reported, and is characterized by prolonged
sleep onset latency (SOL).
In general, sleep problems are among the most com-
mon complaints in childhood, with a prevalence of 6 %,
as reported by parents [19]. In comparison, 50–60 % of
children with ADHD experience sleep problems [20];
when children with ADHD are treated with stimulant
medication, the prevalence of initial insomnia increases
to 64–70 % [21]. Sleep problems not only have negative
impacts on a child’s social, physical, and mental well-
being [20], but lead to exhaustion and high stress levels
in parents [22].
Treatment of insomnia
Nonpharmacological interventions such as improving
sleep hygiene are generally preferred as first-line treat-
ment. Sleep hygiene entails a variety of strategies to pro-
mote the quantity and quality of sleep, such as avoiding
strenuous play/exercise before bed; going to bed at a
consistent time in a quiet, dark room; establishing con-
sistent waking times; getting regular physical exercise;
and maintaining a regular daily routine [23]. Although it
is considered the first line of treatment, preliminary
research suggests sleep hygiene has limited effectiveness
in pediatric ADHD [24]. Weiss and colleagues found
that sleep hygiene on its own only helped a small frac-
tion (15 %) of children with ADHD [22].
The use of pharmacological agents to promote sleep is
common, but evidence regarding safety and effectiveness
for pediatric use is lacking [20]. Children with ADHD
are more likely to be prescribed medications with hyp-
notic properties such as clonidine or antihistamines to
promote sleep; however, the safety and effectiveness for
this off-label use have not been established in children
[25]. At present, no approved medications exist for
childhood insomnia in Canada or Australia [26]. In the
absence of approved pharmacotherapy, Canadian and
Australian healthcare providers recommend the most
popular natural health product (NHP) for sleep: mela-
tonin [27].
Melatonin
First discovered in 1958 [20], melatonin is a hormone
released by the pineal gland and regulates the sleep-
wake cycle [28, 29], thermoregulatory cycle [30], repro-
ductive rhythm [31], and immune function [32]. Its
secretion follows a circadian rhythm that is entrained to
the light/dark cycle and is regulated by the hypothalamic
suprachiasmatic nucleus (the central pacemaker of the
body) [28]. The secretion of melatonin is suppressed by
daylight but increases with darkness; it regulates the cir-
cadian rhythm by promoting the desire to sleep at night
[28]. Individuals with neurodevelopmental disorders
often have biological clock or circadian rhythm distur-
bances, which result in sleep disorders [29]. Children
with ADHD have a delayed endogenous circadian
pacemaker as measured by delayed sleep onset, dim-
light melatonin onset, and time of awakening [33–35].
These findings suggest that melatonin may be particu-
larly effective in children with ADHD to help promote
sleep onset by two possible routes: as a chronobiotic
and as a hypnotic.
Classified as an NHP by Health Canada (HC), melatonin
is available over the counter [36]. In Australia, melatonin
may be obtained with a prescription or without, by order-
ing it through the internet. Melatonin is widely used in
pediatric populations for the treatment of sleep disorders
[37]. A 2003 survey of 671 US community-based pediatri-
cians reported that approximately 25 % of physicians
recommended melatonin for sleep problems in toddlers
(1–8 %) and adolescents (15–19 %) [26]. A 2013 study
conducted in Australia found that melatonin was pre-
scribed 89.1 % of the time for poor sleep initiation in chil-
dren by general pediatricians [27].
Members of our team conducted a systematic review
on the efficacy of melatonin for the treatment of sleep
disorders in an evidence report for the Agency for
Healthcare Research and Quality in 2004 [28]. We
Punja et al. Trials  (2016) 17:375 Page 2 of 10
identified six trials of adults and children reporting SOL
who had a secondary sleep disorder; meta-analysis fa-
vored melatonin but was nonsignificant (-13.2 min; 95 %
CI: -27.3, 0.9) [38]. Our systematic review findings were
limited by too few studies of inadequate sample sizes (n
= 7–30). A more recent review identified four studies in-
vestigating the use of melatonin for insomnia in children
[20]. These studies included an open-labeled study, two
randomized controlled trials (RCTs) and one 3-year
follow-up study [22, 39, 40]. All studies showed signifi-
cant improvement in SOL in the treatment arms; how-
ever, the trials were limited by small sample sizes,
variable SOL criteria, ADHD criteria, and treatment as-
sessments, and a lack of generalizability.
N-of-1 Trials
A major barrier to the conduct of RCTs of NHPs is
participant access to the study product without a pre-
scription (personal communication, National Center for
CAM, US National Institutes of Health). Since mela-
tonin is readily available in Canada, parents may (1) pre-
fer to buy it themselves instead of risking their child
being randomized to a placebo control arm or (2) con-
taminate an RCT by administering nonstudy melatonin
to their child. An ideal alternative to an RCT is an N-of-
1 trial, defined as a prospective, multiple-crossover,
placebo-controlled, triple-blind, randomized trial in a
single subject. In an N-of-1 trial, each participant is
assured of receiving both the study medication and pla-
cebo, and thus learns whether the treatment works spe-
cifically for them or not.
Melatonin is an optimal treatment for testing within
an N-of-1 trial framework for several reasons: (1) it has
a short half-life (0.54–2 h) [28]; (2) no residual impact
remains on the target symptom after excretion [38]; and
(3) it is being used to treat an important and recurrent
symptom that has a negative impact on quality of life
and compliance with ADHD stimulant treatment [22].
Why is this trial needed now?
More than 1000 controlled clinical trials have evaluated
melatonin for the treatment of sleep disorders [28], but
the literature for children with ADHD is limited to very
few studies confounded by small sample sizes and lim-
ited clinical applicability [20]. The fact that melatonin is
being widely used in this population despite the absence
of high-quality clinical evidence highlights the need for a
well-designed RCT. Our proposed study will overcome
the recurring limitations of small sizes in pediatric trials
by adequately powering the parallel-group trial and of-
fering each participant an N-of-1 trial to promote trial
enrollment. To our knowledge, this will be the first pro-
spectively planned head-to-head comparison of parallel
group RCTs and N-of-1 trials.
Objectives
The primary objectives of this study are to (1) determine
the effectiveness of weight-based dosing of melatonin for
initial insomnia (i.e., reducing sleep onset latency) in
children and adolescents with ADHD who are receiving
stimulant medication and (2) determine whether N-of-1




We will conduct a prospectively planned, head-to-head
comparison of a parallel-group RCT design with aggre-
gated N-of-1 trial data. The trial is a multicenter,
randomized, triple-blind, placebo-controlled series of N-
of-1 trials with an embedded RCT. Half the participants
will be randomly allocated to melatonin in the first
period; the other half will start with placebo; and the
RCT will include the data from the first period only. For
the N-of-1 trial, each participant will undergo three pairs
of treatment/placebo periods (each period is 1 week
long, and each N-of-1 trial will last a total of 6 weeks).
See Fig. 1 for scheme of the study design, Fig. 2 for flow
of participants through study, and the SPIRIT checklist
(Additional file 1).
Study setting
The trial sites will be outpatient pediatric and/or family
medicine clinics at hospital and community clinics in
Australia and in Edmonton, Canada. Staff in all relevant
clinics will be informed about the availability of the trial
and will refer participants to the study investigators at
each site. Community patients will also be able to be re-
ferred by their physician.
Study participants
To be included in the trial, participants must (1) be be-
tween the ages of 6 to 17 years; (2) have a diagnosis of
ADHD according to the DSM-IV criteria; (3) be on a
stable dose of stimulant medication for at least 1 month
prior to the study; and (4) have an SOL of ≥ 45 min, ≥ 3
nights/week, for ≥1 month. Exclusion criteria include (1)
children with comorbid psychiatric/neurological diagno-
sis that may affect sleep; (2) children with untreated ob-
structive sleep apnea, untreated sleep-related breathing
disorder, untreated narcolepsy, sleep-related movement
disorders, parasomnias, adjustment insomnia, insomnia
due to drug use or mental health issues, or secondary
enuresis; (3) children with a known allergy or hypersen-
sitivity to melatonin or other study drug ingredients; (4)
children on immunosuppressive drugs, blood pressure
drugs, selective serotonin reuptake inhibitors or anti-
coagulant drugs; and (5) children not on a regular seda-
tive/hypnotic medication, whose parents do not agree
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not to alter the daily dose of these for the duration of
the trial; children with active or uncontrolled disorders
(hormonal disorders, diabetes, liver disease, abnormal
kidney function, untreated kidney disease or blood
clotting disorders); (6) children with seizure disorders;
(7) breastfeeding or pregnant women; (8) female partici-
pants with child-bearing potential not practicing an ac-
ceptable form of birth control throughout the trial (in
Australia, females who are ≥ 12 years who are menstruat-
ing and sexually active); (9) participants who disagree to
not driving or operating heavy machinery within 8 hours
of ingestion of study medication; and (10) children
whose parent/primary caregiver does not understand
English, have a phone, or provide informed consent.
Interventions
Sleep-hygiene phase
Upon recruitment, all participants/parents will receive
an information sheet and a 15-min counseling session to
review optimal sleep hygiene. The family will be asked












Fig. 2 Flow of participants through study
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to try the sleep-hygiene strategies suggested for 14 days.
At day 7, the research assistant will telephone the fam-
ily to ensure that sleep hygiene measures are imple-
mented and address any barriers. If the child is still
eligible for the study at day 14, the child will be offered
enrollment into the trial. While sleep hygiene is an im-
portant first step, preliminary data suggest that only
15 % of children will respond [22]. Therefore, the ma-
jority of those pre-enrolled are anticipated to continue
on to trial enrollment. Randomization will not occur
until trial enrollment.
Melatonin
Previous research suggests that an oral dose of 2.5–
10 mg before or at the desired bedtime is well tolerated
in children [41]. Similar to previous pediatric trials [40],
we will use weight-based dosing, giving 3 mg of sublin-
gual melatonin to those children who are < 40 kg and
6 mg to those ≥ 40 kg. Melatonin will be taken once
daily, 30 minutes prior to bedtime. Placebo with an iden-
tical appearance has been manufactured. The clinical
effect of melatonin is rapidly evident, and melatonin has
a short half-life (0.54–2 h). Therefore, an appropriate
duration of each treatment period is 1 week. Data from
day 1 of each period will be discarded to provide a wash-
out period. If a carryover effect is found subsequent to
day 1, appropriate adjustments will be made, e.g., dis-
carding an extra day’s data.
Randomization
Participants will undergo three pairs of treatment with
melatonin and placebo. In each pair, the order of treat-
ment will be randomized. In particular, the first period
for each patient will be randomized in variable block
sizes of 4 and 6, stratified by age (<12 and ≥ 12 years)
and country (Canada or Australia), to ensure a balance
of the treatment groups for the parallel-group RCT. The
randomization code will be developed by the study stat-
istician. The randomization code will be provided to the
central research pharmacy for each participating site and
to maintain the blind. When a participant has been
enrolled, the research pharmacy will randomize the sub-
ject based on the master randomization list and courier
six bottles numbered 1–6, corresponding to each week’s
treatment. Each bottle will contain seven capsules (or 14
for children who weigh < 40 kg) to be taken over 7 days.
Randomization codes will be kept by the research phar-
macy in case the code needs to be broken for safety
reasons as determined by the Data Safety and Monitor-
ing Board (DSMB).
Blinding
The trial will be triple-blinded (participant, healthcare
provider, and statistician). The placebo has the same
appearance, volume, weight, odour, and taste as the ac-
tive product. There will be unblinding of the individual
participant’s randomized N-of-1 sequence for the health-
care provider and participant only upon receiving indi-
vidual trial reports or on participant request to stop the
trial early.
Cointerventions
All participants will be encouraged to continue prac-
ticing good sleep hygiene consistently throughout their
N-of-1 trial. Participants will receive other medications
and healthcare tests their primary physician deems
appropriate. If a child is already on the following medi-
cations, we will require stable doses of each: approved
anti-depressants, anxiolytics, sedatives/hypnotics, and
clonidine throughout the 6-week trial. If not already tak-
ing these medications, the child may not start them
regularly during the trial. It is preferable that partici-
pants abstain from coffee, alcohol, and high caffeine
energy drinks for 1 week prior to the sleep-hygiene
phase, during the sleep-hygiene phase, and during the
trial itself. Any caffeine intake during the previous week
will be recorded during the sleep hygiene phase, at base-
line, and at the end of each week during the trial.
Any changes in dose/frequency/type of stimulant
treatment for ADHD and whether the patient is taking
nontrial melatonin will be recorded throughout the trial.
Contamination
Because melatonin is readily available over the counter
in Canada, contamination (parents providing melatonin
to their child) could potentially pose a risk. The use of
N-of-1 trials is expected to prevent this from occurring,
as parents are guaranteed that their child will receive
melatonin during the course of the trial. To further
reduce contamination, parents will be reminded that
their child will be on active therapy in a blinded fashion,
and they would not want to “double dose” their child.
Physician information letters will be sent to the child’s
doctor to remind them not to recommend melatonin
during the study.
Sample size
A proposed sample size was calculated for the parallel
group RCT. The null hypothesis is that both group
means are equal, and the alternative hypothesis is SOL
will be 42 minutes on melatonin and 72 minutes on pla-
cebo [22]. To account for a potential dropout of 25 %,
we assume that 25 % of the participants will show no
effect of treatment and will therefore have a SOL of
72 minutes under both treatments. The average time in
the treatment group will then be 49.5 minutes (as ¾ will
have a time of 42, and ¼ a time of 72). The intent-to-
treat effect will then be a 22.5-minute reduction in SOL.
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Assuming a pooled standard deviation of 60 minutes
[22], randomization of 150 patients per group (300 total)
will provide 90 % power with a type I error rate of 0.05
using a two-sided test. We will need to recruit 177
patients per group (354 total) to commence the sleep-
hygiene phase in order to account for the 15 % of indi-
viduals expected to respond to sleep hygiene. Because
the N-of-1 design will use multiple crossovers for each
patient, this sample size will also achieve sufficient
power for the aggregated N-of-1 analysis.
Proposed trial outcome measures
Primary outcomes
SOL (in minutes) will be measured daily by sleep diaries
completed by parents. Participants who are > 12 years
will assist in filling out sleep diaries. Sleep dairies are
among the most common assessment tools in sleep re-
search [28, 42].
Secondary outcomes
In a subgroup of children, SOL (minutes) will also be mea-
sured daily by actigraphy, which are validated to measure
sleep quality in clinical research [43]. We will use Actiwatch
Spectrum (Phillips Respironics, Murrysville, PA, USA). The
mean amount of time awake at night (minutes) and mean
duration of sleep while in bed (minutes) will be mea-
sured daily by sleep diaries and actigraphy. The num-
ber of awakenings after sleep onset will be measured
by sleep diaries. Sleep efficiency (proportion of time
spent asleep while in bed) will be measured daily by
actigraphs. Daytime behavior, specifically core ADHD
symptoms, will be measured weekly by the Conners’ 3
Parent Short form [44]. The quality of life of the par-
ticipants will be measured weekly by the Pediatric
Quality of Life Inventory-32 [45]. The parent’s quality
of life and fatigue will be measured weekly by the
SF12-v2 [46]. See Table 1 for a list of outcome mea-
sures used in this study.
Adverse events
Each participant will receive ongoing safety monitoring
throughout the trial. Parents will be asked about side
effects during weekly telephone follow-ups. All adverse
events will be forwarded to the DSMB. The DSMB con-
sists of three members with clinical, methodological, and
NHP expertise who are independent of the trial. The
DSMB will review all documented harms during the
study and adjudicate them with regards to causality. Fre-
quency and severity of any adverse events will be re-
ported using the Clinical Trial Adverse Event form that
includes open-ended questions on potential adverse re-
actions. Health Canada and Therapeutic Goods Australia
will be informed of all serious adverse events (those war-
ranting hospitalization) within 7 days.
Withdrawal
If participants experience intolerable adverse events,
they may choose to withdraw, or the investigators may
make this decision in the best interest of the patient.
Patients who are lost to follow-up, who cannot be
contacted for telephone follow-ups, or who wish to dis-
continue medication for 7 or more consecutive days will
be withdrawn. If a participant chooses to withdraw, a
withdrawal report form will be completed. Assessments
and reason(s) for withdrawal will be recorded.
Early stopping (within a treatment period)
While pre-specifying the number of paired periods in an
N-of-1 trial strengthens statistical analysis of the data
[47], N-of-1 trials may accommodate early stopping
within a treatment period. Early stopping most com-
monly occurs for three reasons—perceived lack of effect-
iveness, a dramatic improvement in the target outcome
or safety concerns. If a participant/parent feels strongly
that a period should be stopped early, the research nurse
will give them the option of switching to the next
period’s medication after day 4 of that period, rather
than withdrawing from the trial. Early stopping does not
compromise the validity of the data acquired as all
decisions are made with the blind intact, and the
randomization sequence unaltered. Early stopping within a
treatment period (i.e., early progression to the next treat-
ment period) promotes trial completion, as opposed to
withdrawal, as participants recognize that we will try to ac-
commodate their requests within the confines of the study.
Statistical analysis plan
We will undertake (1) a standard parallel-group RCT
analysis comparing results from the first period for
Table 1 List of outcome measures used
Outcome Tool Frequency of
measurement
SOL Sleep diary Daily
Actigraphy







Sleep efficiency Actigraphy Daily
ADHD Symptoms Conners’ 3 Parent
Short form
Weekly
Participant quality of life Pediatric Quality of
Life Inventory-32
Weekly
Parent quality of life
and fatigue
SF12-v2 Weekly
Adverse events Clinical trial adverse
event form
Daily
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treatment and control groups; (2) analysis of individual
N-of-1 trials; and (3) aggregated analysis across N-of-1
studies using data from all periods in all participants.
Each analysis will report an estimate of the mean differ-
ence between treatment groups across the measure-
ments taken over the course of the trial together with
95 % probability intervals and a probability estimate of
the likelihood of a treatment effect. Primary analyses will
use the Bayesian method with noninformative prior dis-
tributions. We will also carry out analyses based on rea-
sonable weakly informative priors and on the likelihood
alone as a check on sensitivity to assumptions about the
prior distribution. Data on randomized patients at base-
line will be summarized with descriptive statistics (mean,
median, standard deviation, and ranges) for quantitative
variables, and counts and percentages for categorical
variables. Regression adjustments will be carried out for
variables found to be unbalanced at baseline between
treatment and placebo groups. A variety of interaction
tests will be carried out to test for subgroup differences.
Parallel-group RCT analysis
Using data from the first treatment period, we will com-
pare those who received melatonin with those who re-
ceived placebo based on intent-to-treat for all outcomes
adjusted for the average baseline SOL determined by the
pre-randomization sleep-hygiene phase. Outcomes
measured daily will be analyzed both with time series
methods and by using the outcome averaged across the
treatment period. Outcomes measured weekly provide
only one measurement per participant. Secondary ana-
lyses will examine effects defining treatment as that ac-
tually received.
Analysis of individual N-of-1 trials
At the end of each participant’s N-of-1 trial, a patient re-
port will be forwarded to the referring physician in order
to guide treatment decision. The patient report will
present (1) the child’s SOL (according to parent diaries)
for each day of the study; (2) the child’s mean and me-
dian SOL on both treatments; (3) whether the child’s
SOL has normalized below 30 minutes; (4) whether the
SOL is within the parent’s expectations of significant im-
provement; and (5) any reported adverse events. The pa-
tient and physician will make an individual decision
about the continued use of melatonin.
Aggregated analysis
N-of-1 trials will be combined using a multilevel random
effects model that incorporates variance within and be-
tween patients. This within-patient level will incorporate
variation resulting from the treatment crossovers as well
as time effects modeled in various forms (e.g., linear
trends, nonlinear trends, and carryover effects). Each
within-patient regression coefficient will be treated as a
random effect that can vary based on these between-
patient factors. The primary analysis will calculate the
average treatment effect (i.e., will model the mean of the
individual treatment effects as a constant). Secondary
analyses will model the mean as a function of factors
that vary among patients such as age, sex, and dose.
These terms describe the main effects of these factors,
their interactions with the treatment, and their inter-
action with time. A full list of the factors evaluated for
these subgroup analyses is given below.
The full multilevel model will return estimates of both
average effects across the population of patients, as well
as effects for individuals informed by the results on
other participants. The predicted effects for an individ-
ual are weighted averages of the individual’s data and the
averages from others. This model incorporates correla-
tions among the measurements within an individual. It
also enables comparison of the individual’s predicted
treatment effect using the multilevel model with that
from using only that individual’s data.
Carryover, the phenomenon whereby the effects of one
treatment may continue to affect the outcomes mea-
sured after the next treatment is started, is always a risk
in crossover studies. It is not expected that placebo ef-
fects would carry over into a melatonin period, but
melatonin effects may carry over into a placebo
period. Carryover might also differentially affect mea-
surements made in a melatonin treatment period that
follows another melatonin treatment period. We will
investigate various adjustments for carryover, such as
discarding the first measurements in a treatment
period on outcomes measured daily, to determine
whether results are sensitive to carryover. These ad-
justments will allow for potential differential carryover
by treatment regimen.
Bayesian models will be estimated using Markov chain
Monte Carlo with model assessment using posterior pre-
dictive checks [48] and the deviance information criterion
[49]. Non-Bayesian models will be fit using generalized
linear and nonlinear mixed models.
Missing data
For the aggregated N-of-1 trial analysis, we will develop
appropriate missing data models based on the data-
missingness mechanism. We will first check if the data are
missing completely at random and if not, as is likely, will
adjust for observed variables related to missingness using,
if possible, longitudinal fixed or random effects models,
assuming the mean and covariance structures are known.
If considerable data are missing on key predictors, we will
use multiple imputation. As a sensitivity analysis, we will
also analyze differences between groups at each time point
imputing a change of zero for those missing follow-up.
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Interim safety analysis
After 100 participants have been enrolled or after one
year, whichever occurs first, the DSMB will supervise
one interim analysis for safety only using treatment la-
bels (A and B) without knowledge of the identity of each
label to determine if there is an excess of adverse events
in one group. A p value of 0.10 will be used as a decision
criterion for stopping the study for harm. As no effect-
iveness endpoint will be evaluated, there will be no need
to adjust the sample size.
Subgroup analyses
Primary subgroup analyses include the two main stratifi-
cation factors: (1) age (<12, ≥ 12 years) and (2) country
(Australia and Canada). Exploratory analyses will look at
(3) the type of stimulant, (4) weight-adjusted dose of
stimulant, (5) presence of psychiatric comorbid illness,
(6) gender, (7) calendar time of enrollment as a proxy
for differences by climactic season, (8) severity of SOL,
and (9) referring physician/clinic.
Data management
The Women and Children’s Health Research Institute
(WCHRI) at the University of Alberta will be in charge
of data management. WCHRI staff will check data
entered online by participants/parent/guardians and re-
search assistants, identifying queries for research assis-
tants to resolve. Each participant’s N-of-1 data will be
communicated back to each participant’s physician by
fax directly, thereby fulfilling our obligation to all partic-
ipants without biasing staff (i.e., project manager, re-
search assistants, and study statistician will not be
informed of the trial results as they accrue). Regular data
quality checks will be undertaken through automated
data validation checks. Data collected from the acti-
graphs will be downloaded to a computer and reviewed
for completeness and errors.
Discussion
Impact of research
A great need exists to address the current information gap
regarding the effectiveness of melatonin use on sleep distur-
bances in children with the greatest clinical need such as
those on stimulants to treat ADHD. Our novel approach
will not only answer this clinical question, it will also allow
a rigorous comparison of the advantages and disadvantages
of aggregated N-of-1 trials versus a parallel-group RCT.
This method has the potential to become the gold standard
in the accumulation of high-grade evidence to support clin-
ical therapies in chronic disease management.
Trial governance
The study will be overseen by the Trial steering commit-
tee (TSM), which is comprised of the Principal
investigator, co-investigators, research coordinator, and
study statistician. The TSM will be responsible for en-
suring that the study is conducted within appropriate
and professional ethical guidelines, ensuring the good
clinical practice guidelines are observed at all times.
Furthermore, the DSMB, which consists of three
members with clinical, methodological, and NHP ex-
pertise who are independent of the trial will review all
documented harms during the study and adjudicate
them with regard to causality.
Any significant amendments to the protocol will be sub-
mitted to Health Canada, Therapeutic Goods Australia,
and to the University of Alberta and University of
Queensland ethics committees for approval. Trial regis-
tries will also be notified of any major amendments.
The trial sponsor is the University of Alberta. The
sponsor has no role in the trial design; collection, man-
agement, analysis or interpretation of data; writing of
reports; and submission for publication.
Trial status
Recruitment began in March 2015.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOCX 61 kb)
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